AI reveals how glucose helps the SARS-CoV-2 virus
Monday 16 August 2021
Why do some people get sick and die from COVID-19 while others seem to be completely unaffected? EPFL’s Blue Brain Project deployed its powerful brain simulation technology and expertise in cellular and molecular biology to try and answer this question Lausanne, 2 August 2021. A group in the Blue Brain assembled an AI tool that could read
hundreds of thousands of scientific papers, extract the knowledge and
assemble the answer - A machine-generated view of the role of blood glucose levels in the severity of COVID-19 was published today by Frontiers in Public Health, Clinical Diabetes. In response to the COVID-19 pandemic, the COVID-19 Open Research Dataset (CORD-19) of
over 400,000 scholarly articles was made open access, including over
150,000 with full text papers related to COVID-19, SARS-CoV-2, and other
coronaviruses. The CORD-19 dataset is the most extensive coronavirus
literature collection available for data mining to date and the
coalition behind it has challenged AI experts to apply their skills in
natural language processing and other machine learning techniques in
order to generate new insights that may help in the ongoing fight
against COVID-19. “Since early 2020, Blue Brain has been
proactively contributing to the fight against COVID-19,” explains Prof.
Henry Markram, Founder and Director of the Blue Brain Project. “With
this call to action, we realized we could use our Machine Learning
technologies and Data and Knowledge Engineering expertise to develop
text and data mining tools required to try and help the medical
community. Blue Brain set out to answer one of the most puzzling aspects
of this pandemic – why some people get very sick, while others are
completely unaffected”. Building and using the text and data mining tools Accordingly,
Blue Brain built and trained machine-learning models to mine these
papers and extract structured information from text sources. A simple
analysis by this text mining toolbox ‘Blue Brain Search’
of the CORD-19v47 dataset revealed papers that all pointed to glucose
metabolism as the most frequently mentioned biological variable. Using Blue Graph,
a unifying Python framework that analyses extracted text concepts to
construct knowledge graphs, the group constructed specific knowledge
graphs to focus on all the findings that considered glucose in the
context of respiratory diseases, coronaviruses, and COVID-19. This
allowed for the exploration of the potential role of glucose across many
levels, from the most superficial symptomatic associations to the
deepest biochemical mechanisms implicated in the disease. From the
facts and findings of thousands of papers mined, multiple lines of
evidence emerged that elevated blood glucose levels were either caused
by abnormal glucose metabolism, or induced during hospitalization, drug
treatments or by IV administration. This approach correlated extremely
well with COVID-19 severity across the population and revealed how
elevated glucose helps virtually every step of the viral infection, from
its onset in the lungs, through to severe complications such as Acute
Respiratory Distress Syndrome, multi-organ failure and thrombotic
events. “Subsequently, in the paper, we discuss the potential
consequences of this hypothesis and propose areas for further
investigation into diagnostics, treatments and interventions that may
help to reduce the severity of COVID-19 and help manage the public
health impact of the pandemic,” discloses Blue Brain’s Molecular
Biologist Dr. Emmanuelle Logette. The potential of open access scientific papers “Scientists
immediately went to work when the pandemic started and within a year
published over a hundred thousand papers. But, can anyone read so many
papers? Can anyone see and understand all the patterns across all this
research?” asks Prof. Henry Markram. “Fortunately, the coalition behind
the CORD-19 dataset convinced all subscription publishers to bring these
papers over the subscription paywall and make them openly accessible so
that they can be mined with modern machine learning and knowledge
engineering technologies”. “With access to the CORD-19 dataset,
Blue Brain quickly assembled an AI tool and targeted it to try and find
out why some get sick and others not. Is it enough to just say that
older people are more vulnerable? We must find out why. Why do some
apparently healthy people die from COVID-19? Why do so many people die
in the ICU? To answer these questions, we directed our AI to trace every
step of the viral infection from the moment the virus enters the lungs
until the time when the virus breaks out of the cells in the lungs and
spreads throughout the body to infect the organs,” explains Prof.
Markram. “We also built the virus at an atomistic level and developed a
computational model of the infection so we could try to test what was
coming out of the literature. I think we did find the most likely reason
why some people get sicker than others,” he concludes. An example of this is the team using Blue Brain BioExplorer to
visually show the main impacts of high glucose in airway surface liquid
on the primary step of infections in the lung and explaining the
increased susceptibility to respiratory viruses in at-risk patients. Blue
Brain BioExplorer was built to reconstruct, visualize, explore and
describe in detail the structure and function of the coronavirus for
this study, and is open source for others to use to answer key
scientific questions. “Pioneering Simulation Neuroscience to
better understand the brain has numerous collateral benefits,” states
Prof. Markram. “This study shows how Blue Brain’s computing technologies
and unique team of multi-disciplinary experts can quickly be redirected
to help in a global health crisis.” A major step forward for science and understanding the brain “The
COVID-19 study also shows why we believe that computational tools are
so important to help us understand the brain,” explains Prof. Markram.
“The problem is even bigger. There are several million scientific papers
that one would need to read and understand to work out what we know
about the brain. Does anyone know what we know? But, machines can read
so many papers. This is the reason that the Blue Brain has developed
some of the most advanced knowledge engineering, mathematical and
machine learning accelerator technologies. Actually, this solves only a
part of the challenge. With an AI tool that can read all these papers,
we would still only know only a small fraction of what the brain
contains and how it works. But building model brains using design
principles, helps us to try and complete the picture.” he concludes. Is it right to only open science during a pandemic? Prof.
Markram also expressed his frustration with the all too common practice
of locking up of scientific knowledge by subscription publishers. “When
the CORD-19 literature dataset was made available to us, we at Blue
Brain were able to point our technology at COVID-19 and propose an
answer to an important question in the battle against this deadly virus.
Therefore, is it right to only make science papers (that are publicly
funded) open to the public during a pandemic when the same kind of
techniques can be used to help address so many other diseases,
accelerate science, and help save the planet from climate change?” About EPFL’s Blue Brain Project The aim of the EPFL Blue Brain Project,
a Swiss brain research initiative founded and directed by Professor
Henry Markram, is to establish simulation neuroscience as a
complementary approach alongside experimental, theoretical and clinical
neuroscience to understanding the brain, by building the world’s first
biologically detailed digital reconstructions and simulations of the
mouse brain. https://www.epfl.ch/research/domains/bluebrain/
Funding This
study was supported by funding to the Blue Brain Project, a research
center of the École polytechnique fédérale de Lausanne (EPFL), from the
Swiss government ETH Board of the Swiss Federal Institutes of
Technology. References Emmanuelle Logette,
Charlotte Lorin, Cyrille Favreau, Eugenia Oshurko, Jay S. Coggan,
Francesco Casalegno, Mohameth François Sy, Caitlin Monney, Marine
Bertschy, Emilie Delattre, Pierre-Alexandre Fonta, Jan Krepl, Stanislav
Schmidt, Daniel Keller, Samuel Kerrien, Enrico Scantamburlo,
Anna-Kristin Kaufmann, Henry Markram. A machine-generated view of the
role of Blood Glucose Levels in the severity of COVID-19. Frontiers in
Public Health, 28 July 2021. doi.org/10.3389/fpubh.2021.695139
Author: Blue Brain Project
Source: EPFL
|